<乌鸦传媒>Third Person 'Cured' of HIV via Transplant U.S. woman with leukemia gets cord blood resistant to HIV Feb 16, 2022
<乌鸦传媒>Women More Likely to Experience Severe Toxicity of Cancer Treatments Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<乌鸦传媒>Illusionist Criss Angel's Son's Acute Leukemia Famed magician speaks about the long battle Feb 09, 2022
<乌鸦传媒>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<乌鸦传媒>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<乌鸦传媒>Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<乌鸦传媒>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<乌鸦传媒>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<乌鸦传媒>Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<乌鸦传媒>Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
<乌鸦传媒>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<乌鸦传媒>Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
<乌鸦传媒>A Gentler Standard for Acute Promyelocytic Leukemia in Kids ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
<乌鸦传媒>FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemia Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
<乌鸦传媒>What Happens When All the Great Doctors Are Gone? In commemoration of the late Elihu (Eli) Estey, MD Oct 13, 2021
<乌鸦传媒>Life Expectancy Still Lower for Blood or Marrow Transplant Recipients Although late mortality has decreased over the past 40 years Sep 09, 2021
<乌鸦传媒>Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
<乌鸦传媒>Add-On Venetoclax Promising in Younger, Fit AML Patients "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
<乌鸦传媒>IVF Babies at No Increased Risk of Childhood Cancers No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
<乌鸦传媒>Ethics Consult: Help Family Have 'Savior Child' for Marrow Donation? MD/JD Weighs In You voted, now see the results and an expert's discussion Jun 25, 2021
<乌鸦传媒>Fixed-Duration, All-Oral Regimen Slows CLL Progression Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
<乌鸦传媒>Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
<乌鸦传媒>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
<乌鸦传媒>Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patients BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021
<乌鸦传媒>CAR-T Drives High Response in Relapsed/Refractory ALL ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit Jun 06, 2021
<乌鸦传媒>Combination Therapy Achieves High Response in Ph+ ALL Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
<乌鸦传媒>Combo Therapy Boosts Response in Hairy Cell Leukemia Complete response achieved in 26 of 30 patients with vemurafenib/rituximab May 12, 2021
<乌鸦传媒>Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
<乌鸦传媒>Whole-Genome Sequencing Makes a Case in Leukemia Study More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
<乌鸦传媒>Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemia Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
<乌鸦传媒>Ethics Consult: Refuse Treatment for Dictator? MD/JD Weighs In You voted, now see the results and an expert's discussion Jan 15, 2021
<乌鸦传媒>PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
<乌鸦传媒>Chemo-Free Combo Boosts PFS in First-Line CLL PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
<乌鸦传媒>Novel Agent Active in Refractory CML Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
<乌鸦传媒>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
<乌鸦传媒>Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<乌鸦传媒>These Forbes 400 Billionaires Made Their Fortunes in Healthcare 14 individuals, $66 billion in combined net worth Sep 24, 2020
<乌鸦传媒>Raising the Bar for Myelofibrosis Therapy Development Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint Sep 14, 2020
<乌鸦传媒>Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
